Key Takeaways
- Sanofi has signed an $80 million licensing deal with South Korean biotech Adel for Alzheimer’s treatment ADEL-Y01.
- The deal could reach up to $1.04 billion, including royalties, and provides Sanofi exclusive global rights to the therapy.
- ADEL-Y01 is a monoclonal antibody in phase 1 trials, targeting tau protein involved in Alzheimer’s disease.
Sanofi Announces Licensing Agreement for Alzheimer’s Therapy
Sanofi has entered into a significant licensing agreement with Adel, a clinical-stage biotech from Seoul, to develop an antibody therapy for Alzheimer’s disease, known as ADEL-Y01. This deal includes an initial payment of $80 million and has the potential to escalate to $1.04 billion, alongside ongoing royalties.
As part of this agreement, Sanofi will gain exclusive global access to ADEL-Y01, which is noted for its first-in-class potential in treating Alzheimer’s. Additionally, Sanofi will also acquire rights to related backup compounds linked to this therapy.
ADEL-Y01 is a humanized monoclonal antibody intended to specifically target tau protein acetylated at lysine-280 (acK280), a protein influential in the progression of Alzheimer’s and other neurodegenerative diseases. This investigational therapy aims to prevent the aggregation and spread of toxic tau while preserving the function of healthy tau associated with microtubules. The asset was developed through Adel’s research in neural diseases and innovative targeting of tau modification, with co-development initiated alongside South Korean firm Oscotec in 2020. Current assessments place ADEL-Y01 in a global phase 1 trial.
Erik Wallstroem, M.D., Ph.D., Sanofi’s global head of multiple sclerosis, neurology, and gene therapy development, expressed enthusiasm about the partnership, stating, “Adel’s innovative approach to targeting tau acetylation offers a promising and differentiated mechanism for addressing the underlying causes of Alzheimer’s disease.” He emphasized the aim to move ADEL-Y01 through clinical development in hopes of providing new solutions for patients affected by this challenging condition.
Earlier on the same day, Sanofi announced an expanded collaboration with Dren Bio, aimed at discovering and developing an advanced B-cell depleting therapy for autoimmune diseases. This follows another recent partnership with U.S.-based InduPro Therapeutics, also centered on autoimmune conditions.
Despite these positive developments, Sanofi faced challenges with its investigational BTK inhibitor tolebrutinib for non-relapsing secondary progressive multiple sclerosis, which has experienced a delay in FDA review, with a decision now expected by March 2026. Additionally, the company disclosed that tolebrutinib failed to meet expectations in a phase 3 trial for primary progressive multiple sclerosis, prompting Sanofi to forgo seeking regulatory approval for that indication.
The content above is a summary. For more details, see the source article.